公开(公告)号：US20240327334A1

公开(公告)日：2024-10-03

申请号：US18390287

申请日：2023-12-20

申请人： Enanta Pharmaceuticals, Inc.

发明人： Xuri GAO ,  Bin WANG ,  Hui CAO ,  Jiajun ZHANG ,  Yuk Ming SIU ,  Jiang LONG ,  Wei LI ,  Matthew C. RHODES ,  Xuechao XING ,  Jianming YU ,  Scott MITCHELL ,  Yat Sun OR

IPC分类号： C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/40

CPC分类号： C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/4015

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12084407B2

公开(公告)日：2024-09-10

申请号：US17780047

申请日：2020-11-25

申请人： CANOPY GROWTH CORPORATION

发明人： Siawash Ahmar ,  Krishna Kumar Gnanasekaran ,  Jeffrey Alan Omeara

IPC分类号： C07C311/29 ,  A61P3/00 ,  C07C309/75 ,  C07C311/51 ,  C07C317/22 ,  C07D205/06 ,  C07D205/12 ,  C07D207/408 ,  C07D211/54 ,  C07D213/71 ,  C07D233/84 ,  C07D235/16 ,  C07D235/28 ,  C07D239/40 ,  C07D249/08 ,  C07D249/10 ,  C07D263/32 ,  C07D277/30 ,  C07D295/15 ,  C07D295/26 ,  C07D305/08 ,  C07D307/64 ,  C07D487/10

CPC分类号： C07C311/29 ,  A61P3/00 ,  C07C309/75 ,  C07C311/51 ,  C07C317/22 ,  C07D205/06 ,  C07D205/12 ,  C07D207/408 ,  C07D211/54 ,  C07D213/71 ,  C07D233/84 ,  C07D235/16 ,  C07D235/28 ,  C07D239/40 ,  C07D249/08 ,  C07D249/10 ,  C07D263/32 ,  C07D277/30 ,  C07D295/15 ,  C07D295/26 ,  C07D305/08 ,  C07D307/64 ,  C07D487/10 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/14

摘要： The synthesis of a range of pentylbezene-1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors. Accordingly, the use of such synthetic cannabinoids in the treatment of various disorders mediated by CB1 and CB2 is contemplated.

公开(公告)号：US12075785B2

公开(公告)日：2024-09-03

申请号：US17834252

申请日：2022-06-07

申请人： Pro Farm Group, Inc.

发明人： Ratnakar N. Asolkar ,  Marja Koivunen ,  Pamela G. Marrone ,  Ana Lucia Cordova-Kreylos ,  Huazhang Huang

IPC分类号： A01N43/16 ,  A01N43/76 ,  A01N43/86 ,  A01N43/90 ,  A01N57/20 ,  A01N63/20 ,  C07D263/32 ,  C07D263/34 ,  C07D309/14 ,  C07D407/06 ,  C07D413/04 ,  C07D413/06 ,  C07D493/10 ,  C07D498/14 ,  C07D513/04 ,  C12N1/20 ,  C12P17/04 ,  C12P17/06 ,  C12P17/14 ,  C12P17/16 ,  C12P17/18 ,  A01N43/00 ,  C12N1/00 ,  C12R1/00 ,  C12R1/01

CPC分类号： A01N63/20 ,  A01N43/16 ,  A01N43/76 ,  A01N43/86 ,  A01N43/90 ,  A01N57/20 ,  C07D263/32 ,  C07D263/34 ,  C07D309/14 ,  C07D407/06 ,  C07D413/04 ,  C07D413/06 ,  C07D493/10 ,  C07D498/14 ,  C07D513/04 ,  C12N1/20 ,  C12N1/205 ,  C12P17/04 ,  C12P17/06 ,  C12P17/14 ,  C12P17/16 ,  C12P17/18 ,  A01N43/00 ,  C12N1/00 ,  C12R2001/00 ,  C12R2001/01 ,  A01N63/20 ,  A01N43/16 ,  A01N43/74 ,  A01N43/76 ,  A01N43/90

摘要： A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, insects, fungi, weeds and nematodes) is provided. Also provided are natural products derived from a culture of said species and methods of controlling pests using said natural products.

公开(公告)号：US12018004B2

公开(公告)日：2024-06-25

申请号：US18053582

申请日：2022-11-08

申请人： H. Lundbeck A/S ,  THE SCRIPPS RESEARCH INSTITUTE

发明人： Justin S. Cisar ,  Cheryl A. Grice ,  Todd K. Jones ,  Micah J. Niphakis ,  Jae Won Chang ,  Kenneth M. Lum ,  Benjamin F. Cravatt

IPC分类号： C07D295/205 ,  A61P25/22 ,  C07C271/10 ,  C07C271/12 ,  C07D205/04 ,  C07D207/09 ,  C07D207/14 ,  C07D213/38 ,  C07D213/40 ,  C07D213/55 ,  C07D215/42 ,  C07D215/46 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D295/26 ,  C07D307/79 ,  C07D317/46 ,  C07D317/58 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  C07D405/14 ,  C07D407/06 ,  C07D413/06 ,  C07D413/10 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107

CPC分类号： C07D295/205 ,  A61P25/22 ,  C07C271/10 ,  C07C271/12 ,  C07D205/04 ,  C07D207/09 ,  C07D207/14 ,  C07D213/38 ,  C07D213/40 ,  C07D213/55 ,  C07D215/42 ,  C07D215/46 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D295/26 ,  C07D307/79 ,  C07D317/46 ,  C07D317/58 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  C07D405/14 ,  C07D407/06 ,  C07D413/06 ,  C07D413/10 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107

摘要： This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.

公开(公告)号：US20230357221A1

公开(公告)日：2023-11-09

申请号：US18343319

申请日：2023-06-28

申请人： UNIVERSITÉ DE MONTRÉAL

发明人： Yves GAREAU ,  Stéphane GINGRAS ,  Yves CHANTIGNY ,  Gaoqiang YANG ,  Guy SAUVAGEAU ,  Irène BACCELLI ,  Anne MARINIER

IPC分类号： C07D417/12 ,  C07D249/04 ,  C07D263/32 ,  C07D263/34 ,  C07D277/24 ,  C07D413/12 ,  G01N33/50

CPC分类号： C07D417/12 ,  C07D249/04 ,  C07D263/32 ,  C07D263/34 ,  C07D277/24 ,  C07D413/12 ,  G01N33/5011

摘要： Heterocyclic compounds of Formula I:




and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

公开(公告)号：US11760754B2

公开(公告)日：2023-09-19

申请号：US16761210

申请日：2018-11-02

申请人： UNIVERSITÉ DE MONTRÉAL

发明人： Yves Gareau ,  Stéphane Gingras ,  Yves Chantigny ,  Gaoqiang Yang ,  Guy Sauvageau ,  Irène Baccelli ,  Anne Marinier

IPC分类号： C07D413/12 ,  C07D263/32 ,  C07D263/34 ,  C07D417/12 ,  A61K31/421 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/506 ,  A61P35/02 ,  C07D249/04 ,  C07D277/24 ,  G01N33/50

CPC分类号： C07D417/12 ,  C07D249/04 ,  C07D263/32 ,  C07D263/34 ,  C07D277/24 ,  C07D413/12 ,  G01N33/5011

摘要： Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

公开(公告)号：US11662662B2

公开(公告)日：2023-05-30

申请号：US16994957

申请日：2020-08-17

申请人： SAMSUNG ELECTRONICS CO., LTD.

发明人： Hyunji Song ,  Sukkoo Hong ,  Sumin Kim ,  Yechan Kim ,  Juyoung Kim ,  Jinjoo Kim ,  Hyunwoo Kim ,  Juhyeon Park ,  Songse Yi

IPC分类号： G03F7/004 ,  G03F7/039 ,  C07D213/68 ,  C07D263/32 ,  C07D233/64 ,  C07D277/26

CPC分类号： G03F7/0045 ,  C07D213/68 ,  C07D233/64 ,  C07D263/32 ,  C07D277/26 ,  G03F7/0392

摘要： A photo-decomposable compound, a photoresist composition, and a method of manufacturing an IC device, the compound generating acid upon exposure and acts as a quenching base that neutralizes acid in an unexposed state and being represented by Formula 1:






wherein, in Formula 1, Ra is a C5 to C40 substituted or unsubstituted cyclic hydrocarbon group including at least one nitrogen atom, Ya is a C1 to C20 divalent linear or cyclic hydrocarbon group, n is an integer of 1 to 5, and A+ is a counter ion.

公开(公告)号：US20230150927A1

公开(公告)日：2023-05-18

申请号：US17780047

申请日：2020-11-25

申请人： CANOPY GROWTH CORPORATION

发明人： SIAWASH AHMAR ,  KRISHNA KUMAR GNANASEKARAN ,  JEFFREY ALAN OMEARA

IPC分类号： C07C311/29 ,  A61P3/00 ,  C07D295/26 ,  C07C311/51 ,  C07D213/71 ,  C07C317/22 ,  C07C309/75 ,  C07D307/64 ,  C07D233/84 ,  C07D305/08 ,  C07D207/408 ,  C07D211/54 ,  C07D239/40 ,  C07D205/06 ,  C07D205/12 ,  C07D487/10 ,  C07D295/15 ,  C07D249/08 ,  C07D249/10 ,  C07D263/32 ,  C07D277/30 ,  C07D235/16 ,  C07D235/28

CPC分类号： C07C311/29 ,  A61P3/00 ,  C07C309/75 ,  C07C311/51 ,  C07C317/22 ,  C07D205/06 ,  C07D205/12 ,  C07D207/408 ,  C07D211/54 ,  C07D213/71 ,  C07D233/84 ,  C07D235/16 ,  C07D235/28 ,  C07D239/40 ,  C07D249/08 ,  C07D249/10 ,  C07D263/32 ,  C07D277/30 ,  C07D295/15 ,  C07D295/26 ,  C07D305/08 ,  C07D307/64 ,  C07D487/10 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/14

摘要： The synthesis of a range of pentylbezene-1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors. Accordingly, the use of such synthetic cannabinoids in the treatment of various disorders mediated by CB1 and CB2 is contemplated.

公开(公告)号：US20190085173A1

公开(公告)日：2019-03-21

申请号：US15711847

申请日：2017-09-21

申请人： Rohm and Haas Electronic Materials Korea Ltd.

发明人： Jung-June Lee ,  Jae Bong Lim

IPC分类号： C09D5/00 ,  G03F7/09 ,  C07C309/06 ,  C07D239/26 ,  C07D241/12 ,  C07D263/32 ,  C07D277/22

CPC分类号： G03F7/26 ,  C07C309/06 ,  C07D213/26 ,  C07D213/61 ,  C07D213/71 ,  C07D213/75 ,  C07D239/26 ,  C07D241/12 ,  C07D263/32 ,  C07D277/22 ,  C09D5/006 ,  G03F7/004 ,  G03F7/091 ,  G03F7/11 ,  G03F7/40 ,  H01L21/0274 ,  H01L21/0276 ,  H01L21/0332 ,  H01L21/0337 ,  H01L21/311

摘要： New methods and substrates are provided that include antireflective compositions that comprise one or more thermal acid generators.

公开(公告)号：US20190000810A1

公开(公告)日：2019-01-03

申请号：US16064618

申请日：2016-12-27

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： Yoshihiro MURAKAMI ,  Hitoshi MATSUSHITA ,  Kengo MATSUMOTO ,  Minoru OKADA ,  Yohei YUKI ,  Noriyuki KOYAMA ,  Naohiko KANAI

IPC分类号： A61K31/421 ,  A61K47/44 ,  A61K9/06 ,  A61P17/04

CPC分类号： A61K31/421 ,  A61K9/06 ,  A61K47/44 ,  A61P17/04 ,  C07D263/32

摘要： An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.